Literature DB >> 19820417

Chemokine receptor CXCR4 enhances proliferation in pancreatic cancer cells through AKT and ERK dependent pathways.

Xiaoming Shen1, Avo Artinyan, Desmond Jackson, Ryan M Thomas, Andrew M Lowy, Joseph Kim.   

Abstract

OBJECTIVES: We previously detected CXCR4 expression in pancreatic intraepithelial neoplasia (PanIN) tissues and demonstrated CXCR4-enhanced proliferation of PanIN cells. Our objective was to determine if the CXCR4 targets AKT and ERK mediate CXCR4-dependent PanIN and pancreatic cancer proliferation.
METHODS: We exposed cultured murine-derived PanIN, invasive pancreatic cancer (5143PDA) and liver metastasis (5143LM) cells, and human pancreatic cancer PANC-1 cells to CXCL12, the specific CXCR4 ligand, and measured phosphorylation of AKT and ERK1/2. The roles of AKT and ERK1/2 in CXCR4-dependent cell proliferation were assessed by the PI/3K-AKT small molecular inhibitor LY294002 and the ERK signaling inhibitor UO126.
RESULTS: We discovered increases in phosphorylation of AKT in PanIN, 5143PDA, and PANC-1 cells but no increase in 5143LM cells after exposure to CXCL12. We also observed that exposure to CXCL12 over varying periods phosphorylated ERK1/2 in an oscillatory pattern for all cell lines. Administration of LY294002 resulted in complete abrogation of CXCL12-induced proliferation in PanIN, 5143LM, and PANC-1 cells but not 5143PDA cells, whereas UO126 resulted in complete abrogation of CXCR4-enhanced proliferation in all cell lines.
CONCLUSIONS: Our studies show that CXCR4-induced proliferation is mediated by both AKT and ERK signaling in both murine and human pancreatic cancer cells.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19820417     DOI: 10.1097/MPA.0b013e3181bb2ab7

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  26 in total

1.  Suppression of breast cancer proliferation and induction of apoptosis via AKT and ERK1/2 signal transduction pathways by synthetic polypeptide derived from viral macrophage inflammatory protein II.

Authors:  Qingling Yang; Changjie Chen; Zhifeng Yang; Yangjun Gao; Jie Tang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2011-08-07

Review 2.  Targeting the cancer-stroma interaction: a potential approach for pancreatic cancer treatment.

Authors:  Xuqi Li; Qingyong Ma; Qinhong Xu; Wanxing Duan; Jianjun Lei; Erxi Wu
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

3.  CXCR4 promotes GSK3β expression in pancreatic cancer cells via the Akt pathway.

Authors:  Shijie Ma; Qianjun Li; Feng Pan
Journal:  Int J Clin Oncol       Date:  2014-08-23       Impact factor: 3.402

4.  Early pancreatic cancer lesions suppress pain through CXCL12-mediated chemoattraction of Schwann cells.

Authors:  Ihsan Ekin Demir; Kristina Kujundzic; Paulo L Pfitzinger; Ömer Cemil Saricaoglu; Steffen Teller; Timo Kehl; Carmen Mota Reyes; Linda S Ertl; Zhenhua Miao; Thomas J Schall; Elke Tieftrunk; Bernhard Haller; Kalliope Nina Diakopoulos; Magdalena U Kurkowski; Marina Lesina; Achim Krüger; Hana Algül; Helmut Friess; Güralp O Ceyhan
Journal:  Proc Natl Acad Sci U S A       Date:  2016-12-16       Impact factor: 11.205

5.  CXCL12/CXCR4 protein signaling axis induces sonic hedgehog expression in pancreatic cancer cells via extracellular regulated kinase- and Akt kinase-mediated activation of nuclear factor κB: implications for bidirectional tumor-stromal interactions.

Authors:  Ajay P Singh; Sumit Arora; Arun Bhardwaj; Sanjeev K Srivastava; Madhavi P Kadakia; Bin Wang; William E Grizzle; Laurie B Owen; Seema Singh
Journal:  J Biol Chem       Date:  2012-09-20       Impact factor: 5.157

6.  SDF-1/CXCR4 promotes F5M2 osteosarcoma cell migration by activating the Wnt/β-catenin signaling pathway.

Authors:  Yao Lu; Bin Hu; Guo-Feng Guan; Jie Chen; Chun-qiu Wang; Qiong Ma; Yan-Hua Wen; Xiu-Chun Qiu; Xiao-ping Zhang; Yong Zhou
Journal:  Med Oncol       Date:  2015-05-31       Impact factor: 3.064

Review 7.  GPCRs in pancreatic adenocarcinoma: Contributors to tumour biology and novel therapeutic targets.

Authors:  Krishna Sriram; Cristina Salmerón; Shu Z Wiley; Paul A Insel
Journal:  Br J Pharmacol       Date:  2020-04-12       Impact factor: 8.739

8.  CXCL12-CXCR4 signalling axis confers gemcitabine resistance to pancreatic cancer cells: a novel target for therapy.

Authors:  S Singh; S K Srivastava; A Bhardwaj; L B Owen; A P Singh
Journal:  Br J Cancer       Date:  2010-11-02       Impact factor: 7.640

9.  Epidermal Growth Factor Receptor Signaling to the Mitogen Activated Protein Kinase Pathway Bypasses Ras in Pancreatic Cancer Cells.

Authors:  Sangjun Lee; Eileen L Heinrich; Jianming Lu; Wendy Lee; Audrey H Choi; Carrie Luu; Vincent Chung; Marwan Fakih; Joseph Kim
Journal:  Pancreas       Date:  2016-02       Impact factor: 3.327

10.  Stromal cell-derived factor 1α mediates resistance to mTOR-directed therapy in pancreatic cancer.

Authors:  Colin D Weekes; Dongweon Song; John Arcaroli; Lora A Wilson; Belen Rubio-Viqueira; George Cusatis; Elizabeth Garrett-Mayer; Wells A Messersmith; Robert A Winn; Manuel Hidalgo
Journal:  Neoplasia       Date:  2012-08       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.